Rhythm Biosciences Limited

CHIA:RHY Stock Report

Market Cap: AU$22.7m

Rhythm Biosciences Past Earnings Performance

Past criteria checks 0/6

Rhythm Biosciences's earnings have been declining at an average annual rate of -19.8%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 25.6% per year.

Key information

-19.8%

Earnings growth rate

-4.2%

EPS growth rate

Healthcare Industry Growth2.4%
Revenue growth rate25.6%
Return on equity-790.7%
Net Margin-405.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Rhythm Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:RHY Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242-732
31 Mar 242-843
31 Dec 232-954
30 Sep 233-864
30 Jun 233-884
31 Mar 233-874
31 Dec 223-865
30 Sep 223-965
30 Jun 222-965
31 Mar 222-965
31 Dec 212-955
30 Sep 212-845
30 Jun 211-735
31 Mar 211-533
31 Dec 201-432
30 Sep 201-422
30 Jun 200-422
31 Mar 200-421
31 Dec 191-321
30 Sep 191-321
30 Jun 191-331
31 Mar 191-321
31 Dec 180-321
30 Sep 180-221
30 Jun 180-210

Quality Earnings: RHY is currently unprofitable.

Growing Profit Margin: RHY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RHY is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.

Accelerating Growth: Unable to compare RHY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RHY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-25.4%).


Return on Equity

High ROE: RHY has a negative Return on Equity (-790.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 03:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rhythm Biosciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stuart RobertsPitt Street Research Pty Ltd.